Compare WATT & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WATT | NOTV |
|---|---|---|
| Founded | 2012 | 1974 |
| Country | United States | United States |
| Employees | 26 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 19.7M |
| IPO Year | 2014 | 1997 |
| Metric | WATT | NOTV |
|---|---|---|
| Price | $8.67 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 520.8K | 274.9K |
| Earning Date | 02-26-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,018,000.00 | ★ $513,024,000.00 |
| Revenue This Year | $509.64 | $6.49 |
| Revenue Next Year | $210.44 | $4.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 600.23 | 4.54 |
| 52 Week Low | $3.62 | $0.46 |
| 52 Week High | $18.36 | $4.80 |
| Indicator | WATT | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 75.36 | 26.61 |
| Support Level | $6.75 | $0.48 |
| Resistance Level | $9.62 | $0.53 |
| Average True Range (ATR) | 0.76 | 0.04 |
| MACD | 0.32 | -0.00 |
| Stochastic Oscillator | 85.90 | 10.26 |
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.